Evidence map›Paper›PMID 41379393›Full record

ArticleHuman cell2025

Expansion characteristics of CD34

Hezhi Chen, Liying Li, Weiting Guo, Jingjing Zhu, Langyu He, Yuen Yee Cheng, Jie Xu, Yue Kang, Xiujuan Zhang, Kedong Song

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hezhi Chen *Cancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China.
Liying Li *Cancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China.
Weiting GuoCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China.
Jingjing ZhuCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China.
Langyu HeCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China.
Yuen Yee ChengInstitute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Jie XuCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China. jxu@dlut.edu.cn.
Yue KangCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China. kangyue@cancerhosp-ln-cmu.com.
Xiujuan ZhangState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Ocean and Life Science, Panjin Campus, Dalian University of Technology, Panjin, 124221, China. xiujuanzhang@dlut.edu.cn.
Kedong SongCancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian, 116024, China. Kedongsong@dlut.edu.cn.ORCID http://orcid.org/0000-0003-2185-1050

Funding

National Natural Science Foundation of China 31670978/31370991
6 · The paper itself

Abstract

Currently, the ex vivo expansion of hematopoietic stem/progenitor cells (HS/PCs) is one of the effective ways to address the shortage of HS/PCs for clinical transplantation. Therefore, the optimal in vitro expansion strategy for HS/PCs is a critical issue to be addressed in current researches. In this study, we separated UCB Mononuclear cells (MNCs) and CD34

Indexed as

Antigens, CD34Cell Culture TechniquesFetal BloodHematopoietic Stem CellsCell ProliferationCells, CulturedCulture Media, Serum-FreeHumansLeukocytes, MononuclearSuspensionsAntigens, CD34Culture Media, Serum-FreeSuspensionsCD34+ cellsGrowth factorHematopoietic stem/progenitor cellsSerum-freeStatic suspension culture

Identifiers

PMID41379393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.